Neuphoria Therapeutics Inc. Common Stock
$3.79
Market Cap
$20.08M
Shares Outstanding
5.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 16, 2021
Round Lot
100
Locale
US
Day Open
$3.71
Day High
$3.83
Day Low
$3.71
Volume
3.2K
VWAP
$3.76
Prev Close
$3.71
Transactions
--
Acc. Volume
--
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Neuphoria Therapeutics Inc. Common Stock (NEUP) closed the 2026-09-18 session at $3.79, up 2.05% versus the previous close (+0.08). The stock opened at $3.71 and traded between $3.71 and $3.83 during that session. Session trading volume was 3K shares. The volume-weighted average price (VWAP) is $3.76.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Neuphoria Therapeutics Inc. Common Stock has a market capitalization of $20.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NEUP is listed on the XNAS exchange. The company employs approximately 8 people. Neuphoria Therapeutics Inc. Common Stock is headquartered in BURLINGTON, MA. The recorded listing date is 2021-12-16.
On this page you can find market NEUP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.